Estrella Immunopharma Press Releases

• Published on August 6, 2024 - 07:20 GMT

  

  Estrella Immunopharma美国I/II 期EB103 T细胞临床试验完成首位淋巴瘤患者给药

  Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW) EMERYVILLE, CALIFORNIA, UNITED STATES, August 6, 2024 /⁨EINPresswire.com⁩/ -- 美国加利福尼亚州埃默里维尔 -- 临床阶段生物制药公司Estrella Immunopharma, Inc.（纳斯达克代码：ESLA，ESLAW）（“Estrella”或“公司”）今日宣布其I/II期临床试验（STARLIGHT-1 …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on August 1, 2024 - 06:22 GMT

  Estrella Immunopharma Doses First Patient in Phase I/II Trial of EB103 in Advanced B-cell Non-Hodgkin’s Lymphomas

  Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW) EMERYVILLE, CALIFORNIA, UNITED STATES, July 31, 2024 /⁨EINPresswire.com⁩/ -- Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella" or the "Company"), a clinical stage …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on January 30, 2024 - 13:30 GMT

  

  Estrella Immunopharma Announces $1 Million Share Repurchase Authorization

  Estrella Immunopharma (NASDAQ:ESLA) EMERYVILLE, CALIFORNIA, UNITED STATES, January 30, 2024 /⁨EINPresswire.com⁩/ -- Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW ) (“Estrella Immunopharma” or “Estrella”), a clinical-stage biopharmaceutical company …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on January 24, 2024 - 13:30 GMT

  

  Estrella Immunopharma Announces Publication in Blood Demonstrating ARTEMIS T Cell’s Potential in Addressing AML

  Estrella Immunopharma (NASDAQ:ESLA) EMERYVILLE, CALIFORNIA, UNITED STATES, January 24, 2024 /⁨EINPresswire.com⁩/ -- Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella Immunopharma” or “Estrella”), a clinical-stage biopharmaceutical company …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...